Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 241

1.

Tumor Cell-selective Synergism of TRAIL- and ATRA-induced Cytotoxicity in Breast Cancer Cells.

Reinhardt A, Liu H, Ma Y, Zhou Y, Zang C, Habbel JP, Possinger K, Eucker J.

Anticancer Res. 2018 May;38(5):2669-2682.

PMID:
29715087
2.

Pretreatment of BMSCs with TZD solution decreases the proliferation rate of MCF‑7 cells by reducing FGF4 protein expression.

Khoo BY, Nadarajan K, Shim SY, Miswan N, Zang CB, Possinger K, Elstner E.

Mol Med Rep. 2016 Apr;13(4):3406-14. doi: 10.3892/mmr.2016.4959. Epub 2016 Mar 2.

3.

Cisplatin Plus Ifosfamide with/without Etoposide as Salvage Treatment in Heavily-pre-treated Patients with Metastatic Breast Cancer.

Habbel P, Kurreck A, Schulz CO, Regierer AC, Kaul D, Scholz CW, Neumann C, Possinger K, Eucker J.

Anticancer Res. 2015 Sep;35(9):5091-5.

PMID:
26254412
4.

13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013).

Untch M, Gerber B, Harbeck N, Jackisch C, Marschner N, Möbus V, von Minckwitz G, Loibl S, Beckmann MW, Blohmer JU, Costa SD, Decker T, Diel I, Dimpfl T, Eiermann W, Fehm T, Friese K, Jänicke F, Janni W, Jonat W, Kiechle M, Köhler U, Lück HJ, Maass N, Possinger K, Rody A, Scharl A, Schneeweiss A, Thomssen C, Wallwiener D, Welt A.

Breast Care (Basel). 2013 Jun;8(3):221-9. doi: 10.1159/000351692.

5.

An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients.

Regierer AC, Wolters R, Ufen MP, Weigel A, Novopashenny I, Köhne CH, Samonigg H, Eucker J, Possinger K, Wischnewsky MB.

Ann Oncol. 2014 Mar;25(3):633-8. doi: 10.1093/annonc/mdt539. Epub 2013 Dec 23.

6.

Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma.

Meyer AH, Stroux A, Lerch K, Eucker J, Eitle J, Hohloch K, Andrzejak M, Possinger K, Dörken B, Pezzutto A, Scholz CW.

Ann Oncol. 2014 Jan;25(1):210-5. doi: 10.1093/annonc/mdt507.

PMID:
24356632
7.

Treatment of primary breast cancer at the surgical unit of the Charité 1984-1998.

Winzer KJ, Buchholz A, Guski H, Frohberg HD, Diekmann F, Possinger K, Sauerbrei W.

Onkologie. 2013;36(12):727-36. doi: 10.1159/000356805. Epub 2013 Nov 22.

8.

Metastatic breast cancer: are we treating the same patients as in the past?

Ufen MP, Köhne CH, Wischneswky M, Wolters R, Novopashenny I, Fischer J, Constantinidou M, Possinger K, Regierer AC.

Ann Oncol. 2014 Jan;25(1):95-100. doi: 10.1093/annonc/mdt429. Epub 2013 Nov 24.

PMID:
24276026
9.

Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.

Zang C, Eucker J, Liu H, Coordes A, Lenarz M, Possinger K, Scholz CW.

Leuk Lymphoma. 2014 Feb;55(2):425-34. doi: 10.3109/10428194.2013.806800. Epub 2013 Jul 25.

PMID:
23721513
10.

Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.

Karle J, Bolbrinker J, Vogl S, Kreutz R, Denkert C, Eucker J, Wischnewsky M, Possinger K, Regierer AC.

Breast Cancer Res Treat. 2013 Jun;139(2):553-60. doi: 10.1007/s10549-013-2565-3. Epub 2013 May 18.

PMID:
23686417
11.

Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.

Zang C, Eucker J, Liu H, Müller A, Possinger K, Scholz CW.

Cancer Lett. 2013 Oct 10;339(2):288-97. doi: 10.1016/j.canlet.2012.11.013. Epub 2012 Nov 27.

PMID:
23200668
12.

Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancer.

Jehn CF, Flath B, Strux A, Krebs M, Possinger K, Pezzutto A, Lüftner D.

Breast Cancer Res Treat. 2012 Dec;136(3):789-94. doi: 10.1007/s10549-012-2311-2. Epub 2012 Nov 3.

PMID:
23124416
13.

The mTOR inhibitor everolimus in combination with carboplatin in metastatic breast cancer--a phase I trial.

Schwarzlose-Schwarck S, Scholz CW, Regierer AC, Martus P, Neumann C, Habbel P, Liu H, Zang C, Schefe JH, Schulz CO, Possinger K, Eucker J.

Anticancer Res. 2012 Aug;32(8):3435-41.

PMID:
22843927
14.

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.

Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart M, Harbeck N.

Breast Cancer Res Treat. 2012 Aug;134(3):1149-59. doi: 10.1007/s10549-012-2126-1. Epub 2012 Jul 5.

15.

Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.

Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J.

Anticancer Res. 2012 May;32(5):1627-37.

PMID:
22593441
16.

Breast Cancer-Associated Thrombotic Microangiopathy.

Regierer AC, Kuehnhardt D, Schulz CO, Flath B, Jehn CF, Scholz CW, Possinger K, Eucker J.

Breast Care (Basel). 2011 Dec;6(6):441-445. Epub 2011 Dec 15.

17.

Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer.

Jehn CF, Böning L, Kröning H, Possinger K, Lüftner D.

Br J Cancer. 2012 Jan 17;106(2):274-8. doi: 10.1038/bjc.2011.554. Epub 2012 Jan 3.

18.

5FU continuous infusion in heavily pretreated advanced breast cancer patients.

Regierer AC, Reinecke F, Weigel A, Dieing A, Lehenbauer-Dehm S, Schwarzlose-Schwarck S, Possinger K, Eucker J.

Onkologie. 2011;34(12):696-700. doi: 10.1159/000334550. Epub 2011 Nov 21.

PMID:
22156449
19.

Primary tumor excision in stage IV breast cancer at diagnosis without influence on survival: a retrospective analysis and review of the literature.

Rosche M, Regierer AC, Schwarzlose-Schwarck S, Weigel A, Bangemann N, Schefe JH, Scholz CW, Possinger K, Eucker J.

Onkologie. 2011;34(11):607-12. doi: 10.1159/000334061. Epub 2011 Oct 28. Review.

PMID:
22104157
20.

Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance.

Emde A, Mahlknecht G, Maslak K, Ribba B, Sela M, Possinger K, Yarden Y.

Transl Oncol. 2011 Oct;4(5):293-300. Epub 2011 Oct 1.

21.

Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration.

Seidel J, Kunc K, Possinger K, Jehn C, Lüftner D.

Biochem Biophys Res Commun. 2011 Oct 14;414(1):226-32. doi: 10.1016/j.bbrc.2011.09.062. Epub 2011 Sep 17.

PMID:
21945930
22.

The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.

Liu H, Zang C, Schefe JH, Schwarzlose-Schwarck S, Regierer AC, Elstner E, Schulz CO, Scholz C, Possinger K, Eucker J.

Anticancer Res. 2011 Sep;31(9):2713-22.

PMID:
21868512
23.

A comparison of international breast cancer guidelines - do the national guidelines differ in treatment recommendations?

Wolters R, Regierer AC, Schwentner L, Geyer V, Possinger K, Kreienberg R, Wischnewsky MB, Wöckel A.

Eur J Cancer. 2012 Jan;48(1):1-11. doi: 10.1016/j.ejca.2011.06.020. Epub 2011 Jul 7.

PMID:
21741830
24.

[Individualized treatment of breast cancer].

Eucker J, Possinger K.

Dtsch Med Wochenschr. 2011 Mar;136(10):486-91. doi: 10.1055/s-0031-1274532. Epub 2011 Mar 1. Review. German.

PMID:
21365526
25.

High estrogen receptor expression in early breast cancer: chemotherapy needed to improve RFS?

Regierer AC, Wolters R, Kurzeder C, Wöckel A, Novopashenny I, Possinger K, Wischnewsky MB, Kreienberg R.

Breast Cancer Res Treat. 2011 Jul;128(1):273-81. doi: 10.1007/s10549-010-1334-9. Epub 2011 Jan 6.

PMID:
21210206
26.

Association of IL-6, hypothalamus-pituitary-adrenal axis function, and depression in patients with cancer.

Jehn CF, Kühnhardt D, Bartholomae A, Pfeiffer S, Schmid P, Possinger K, Flath BC, Lüftner D.

Integr Cancer Ther. 2010 Sep;9(3):270-5. doi: 10.1177/1534735410370036. Epub 2010 May 11.

PMID:
20702499
27.

Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.

Lux MP, Wöckel A, Benedict A, Buchholz S, Kreif N, Harbeck N, Kreienberg R, Kaufmann M, Beckmann MW, Jonat W, Hadji P, Distler W, Raab G, Tesch H, Weyers G, Possinger K, Schneeweiss A.

Onkologie. 2010;33(4):155-66. doi: 10.1159/000286233. Epub 2010 Mar 19.

PMID:
20389141
28.

Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors.

Schmid P, Kiewe P, Possinger K, Korfel A, Lindemann S, Giurescu M, Reif S, Wiesinger H, Thiel E, Kühnhardt D.

Ann Oncol. 2010 Mar;21(3):633-9. doi: 10.1093/annonc/mdp491. Epub 2009 Oct 30.

PMID:
19880436
29.

Induction of endoplasmic reticulum stress response by TZD18, a novel dual ligand for peroxisome proliferator-activated receptor alpha/gamma, in human breast cancer cells.

Zang C, Liu H, Bertz J, Possinger K, Koeffler HP, Elstner E, Eucker J.

Mol Cancer Ther. 2009 Aug;8(8):2296-307. doi: 10.1158/1535-7163.MCT-09-0347. Epub 2009 Aug 11.

30.

Third consensus on medical treatment of metastatic breast cancer.

Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Köstler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H; Central European Cooperative Oncology Group (CECOG).

Ann Oncol. 2009 Nov;20(11):1771-85. doi: 10.1093/annonc/mdp261. Epub 2009 Jul 16. Review.

PMID:
19608616
31.

Therapeutic implication of BAL in patients with neutropenia.

Kuehnhardt D, Hannemann M, Schmidt B, Heider U, Possinger K, Eucker J.

Ann Hematol. 2009 Dec;88(12):1249-56. doi: 10.1007/s00277-009-0747-1. Epub 2009 May 5.

PMID:
19415277
32.
33.

Compound 48, a novel dual PPAR alpha/gamma ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib.

Bertz J, Zang C, Liu H, Wächter M, Possinger K, Koeffler HP, Elstner E.

Leuk Res. 2009 May;33(5):686-92. doi: 10.1016/j.leukres.2008.11.023. Epub 2009 Jan 7.

PMID:
19131110
34.

Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model.

Lux MP, Hartmann M, Jackisch C, Raab G, Schneeweiss A, Possinger K, Oyee J, Harbeck N.

Breast Cancer Res Treat. 2009 Sep;117(2):305-17. doi: 10.1007/s10549-008-0294-9. Epub 2009 Jan 8.

PMID:
19130218
35.

Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.

Liu H, Zang C, Emde A, Planas-Silva MD, Rosche M, Kühnl A, Schulz CO, Elstner E, Possinger K, Eucker J.

Eur J Pharmacol. 2008 Sep 4;591(1-3):43-51. doi: 10.1016/j.ejphar.2008.06.026. Epub 2008 Jun 12.

PMID:
18588872
36.

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M.

J Clin Oncol. 2008 Apr 1;26(10):1664-70. doi: 10.1200/JCO.2007.13.5822. Epub 2008 Mar 3.

PMID:
18316794
37.

Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up.

Zander AR, Schmoor C, Kröger N, Krüger W, Möbus V, Frickhofen N, Metzner B, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Kreienberg R, Schumacher M, Jonat W.

Ann Oncol. 2008 Jun;19(6):1082-9. doi: 10.1093/annonc/mdn023. Epub 2008 Feb 27.

PMID:
18304964
38.

Prescription pattern of aromatase inhibitors for the adjuvant therapy of breast cancer in Germany - results of the second survey among gynaecologists and medical oncologists.

Lüftner D, Scheller J, Kölm P, Possinger K.

Onkologie. 2008 Feb;31(1-2):19-25. doi: 10.1159/0000111761. Epub 2008 Jan 22.

PMID:
18268395
39.

A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.

Schmid P, Kühnhardt D, Kiewe P, Lehenbauer-Dehm S, Schippinger W, Greil R, Lange W, Preiss J, Niederle N, Brossart P, Freier W, Kümmel S, Van de Velde H, Regierer A, Possinger K.

Ann Oncol. 2008 May;19(5):871-6. doi: 10.1093/annonc/mdm569. Epub 2008 Jan 21.

PMID:
18209010
40.

Contrast-Enhancing Meningeal Lesions Are Associated with Longer Survival in Breast Cancer-Related Leptomeningeal Metastasis.

Regierer AC, Stroux A, Kühnhardt D, Dieing A, Lehenbauer-Dehm S, Flath B, Possinger K, Eucker J.

Breast Care (Basel). 2008;3(2):118-123. Epub 2008 Apr 15.

41.

[Systemic therapy of male breast cancer].

Eucker J, Kühnl A, Possinger K.

Zentralbl Chir. 2007 Oct;132(5):396-9. German.

PMID:
17907081
42.
43.

Clinical value of bisphosphonates in cancer therapy.

Lüftner D, Henschke P, Possinger K.

Anticancer Res. 2007 Jul-Aug;27(4A):1759-68. Review.

44.

The effect of induced hyperthermia on the immune system.

Dieing A, Ahlers O, Hildebrandt B, Kerner T, Tamm I, Possinger K, Wust P.

Prog Brain Res. 2007;162:137-52. Review.

PMID:
17645918
45.

Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.

Schmid P, Untch M, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Lehmann U, Maubach L, Meurer J, Wallwiener D, Possinger K.

J Clin Oncol. 2007 Jun 20;25(18):2509-15.

PMID:
17577027
46.
47.

[Chemotherapy for metastatic breast cancer].

Schmid P, Possinger K.

Zentralbl Gynakol. 2006 Dec;128(6):318-26. Review. German.

PMID:
17213969
48.

Dual PPARalpha/gamma ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines.

Zang C, Liu H, Waechter M, Eucker J, Bertz J, Possinger K, Koeffler HP, Elstner E.

Cell Cycle. 2006 Oct;5(19):2237-43. Epub 2006 Oct 1.

PMID:
17102607
49.

[Treatment of breast cancer: from hormones to antibodies].

Eucker J, Emde A, Possinger K.

Internist (Berl). 2006 Dec;47(12):1223-4, 1226-8. Review. German.

PMID:
17063333
50.

Biomarkers of depression in cancer patients.

Jehn CF, Kuehnhardt D, Bartholomae A, Pfeiffer S, Krebs M, Regierer AC, Schmid P, Possinger K, Flath BC.

Cancer. 2006 Dec 1;107(11):2723-9.

Supplemental Content

Loading ...
Support Center